Good Doctor·Hyperthermic Perfusion | Literature Review and Analysis | (8) “A Comparative Study of the Efficacy of CCCHP and CHP in Treating Malignant Effusions”
Intracavitary hyperthermic perfusion chemotherapy devices can maintain an effective therapeutic temperature within the body cavity and ensure continuous circulation, with efficacy significantly superior to that of single‑dose, non‑circulatory intracavitary hyperthermic perfusion chemotherapy; there was no difference in the incidence of adverse events between the two groups.
2026-08-21

[Abstract]
Study population: A total of 130 patients with malignant effusions, including 89 cases of malignant ascites and 41 cases of malignant pleural effusion, aged 38 to 70 years.
Methods: Control group: Effusion was drained as completely as possible; a chemotherapy‑containing perfusate heated to 45°C was instilled into the body cavity in a single dose and left in situ, with no circulation. Observation group: A body‑cavity hyperthermic perfusion device (Harbin Yuhang Technology Co., Ltd.) was used to deliver continuous, constant‑temperature, circulating hyperthermic perfusion for 60 minutes, after which a portion of the perfusate was retained within the body cavity. A retrospective analysis was conducted to evaluate the efficacy and adverse effects of these two hyperthermic intracavitary chemotherapy regimens in controlling malignant effusions, as well as the temperature gradient between the inlet and outlet fluids at different time points.
Results: In the observation group, the overall response rate (complete remission plus partial remission, CR + PR) was 86%, and the complete remission rate was 31.6%, both significantly higher than those in the control group (57.5% and 17.8%, respectively; P < 0.05). Furthermore, there was a significant difference in the temperature of effusion at the distal end between the two groups, with the disparity becoming more pronounced as the duration increased.
Conclusion: Intracavitary hyperthermic perfusion chemotherapy equipment can maintain an effective therapeutic temperature within the body cavity and ensure continuous circulation, with efficacy significantly superior to that of single‑dose, non‑circulating intracavitary hyperthermic perfusion chemotherapy; there was no difference in the incidence of adverse events between the two groups.
丨Article丨Source丨Core丨Background丨
“Comparative Observation of the Efficacy of CCCHP and CHP in the Treatment of Malignant Effusions” – Clinical Study, Volume 50, Issue 35 (Hu Jun, Chen Jun, Peng Wenjun)
Objective: To retrospectively summarize and analyze the efficacy and adverse effects of hyperthermic intracavitary chemotherapy administered via a hyperthermic intracavitary perfusion system, compared with single‑dose, non‑circulatory hyperthermic intracavitary chemotherapy.
[Keywords] Hyperthermic intraperitoneal chemotherapy, non‑circulating hyperthermic intraperitoneal chemotherapy, malignant ascites


Academic Commentary and Analysis
A Reassessment of the Clinical Value of Intracavitary Hyperthermic Perfusion Chemotherapy in the Treatment of Malignant Effusions
Malignant body cavity effusions are a common complication in patients with advanced cancer. Although conventional hyperthermic intraperitoneal chemotherapy (HIPEC) demonstrates some efficacy, the single‑dose, non‑circulatory infusion method results in rapid heat dissipation and cooling within the cavity, making it difficult to sustain an effective therapeutic temperature and thereby significantly compromising treatment outcomes. This paper takes temperature monitoring as its starting point and, based on clinical data, addresses the core principle of HIPEC: maintaining an effective therapeutic temperature throughout the entire infusion process, rather than merely achieving a brief period of elevated temperature during the initial phase of infusion.
1. Characteristics of the Study Design
This study employed a non-randomized, non-concurrent control design. The control group (73 cases) and the observation group (57 cases) were enrolled from distinct time periods (June 2005–January 2009 vs. January 2009–June 2012). This experimental design did not involve random allocation; rather, it was dictated by the temporal introduction of specific technological equipment. Specifically, prior to January 2009, China lacked clinically available devices for intracavitary hyperthermic perfusion chemotherapy, making it impossible to conduct a randomized, parallel‑group comparison of the two treatment regimens during the same period. Under these objective constraints, the historical control design adopted in this study represented the most feasible research approach at the time.
Another distinctive feature of this study is its precise focus on the core principle of hyperthermic intraperitoneal chemotherapy—maintaining an effective treatment temperature (constant temperature)—and its selection of “outlet‑end temperature” as the primary outcome measure. In the observation group (the device‑utilizing group), the inlet‑end temperature was set at 43.5–44.5°C, with outlet‑end temperatures of 39.5–40.5°C in the peritoneal cavity and 41–42°C in the pleural cavity. This temperature gradient directly reflects the extent of heat loss within the respective cavities; notably, heat loss is more pronounced in the peritoneal cavity, suggesting that “natural heat dissipation” may be related to the volume of fluid present in the cavity. Furthermore, the study measured outlet‑end temperatures at three time points—15, 30, and 60 minutes—and found that, at each interval, the outlet‑end fluid temperature in the observation group was significantly higher than in the control group, with the difference becoming increasingly evident over time (reaching 1.74°C at 60 minutes). These data provide a compelling explanation for the observed differences in therapeutic efficacy: the hyperthermic intraperitoneal chemotherapy device sustains a constant temperature within the body cavity through continuous recirculating heating, whereas a single bolus of infusion fluid subjected to “instantaneous heating” typically results in only “thermal therapy” for most of the infusion period. Such an approach not only fails to effectively kill tumor cells but may also promote the development of heat‑ and drug‑resistant cancer cells.
During the treatment period, neither group received concurrent systemic chemotherapy or immunotherapy, thereby eliminating the confounding effects of other therapeutic interventions and enhancing the comparability between groups.
2. Efficacy is well established.
The results showed that the observation group achieved a complete response rate of 31.6% and an overall effective rate of 86.0%, whereas the control group recorded rates of 17.8% and 57.5%, respectively, with statistically significant differences (P<0.05). The observation group’s overall effective rate was nearly 1.5 times that of the control group, and its complete response rate was more than double—indicating that the clinical application of hyperthermic intracavitary chemotherapy equipment enables a greater number of patients to achieve complete resolution of malignant effusions, thereby substantially improving the quality of life for patients with advanced cancer. This study also observed that some patients who had previously undergone 6–12 sessions of conventional single‑dose, non‑circulating hyperthermic intracavitary chemotherapy without achieving full control of malignant effusions subsequently experienced marked relief after receiving 2–3 sessions of device‑assisted, temperature‑controlled, circulating hyperthermic intracavitary therapy. These clinical outcomes indirectly confirm the advantages of this equipment in managing malignant effusions and suggest that reduced treatment frequency and shorter hospital stays confer indirect economic benefits to patients.
3. Extension of the mechanism of action
The findings of this study not only elucidate the mechanisms underlying hyperthermic intraperitoneal chemotherapy—namely, direct thermal cytotoxicity, chemosensitization, and physical flushing—but also demonstrate that the biological effects of heat–drug synergy are both temperature‑dependent and time‑cumulative. The true value of constant‑temperature, recirculating, hyperthermic perfusion chemotherapy lies in sustaining these mechanisms within a continuous 60‑minute,恒温 environment, thereby effectively killing tumor cells and preventing the recurrence of malignant ascites, rather than relying solely on the brief thermal exposure at the onset of infusion. This sustained thermal therapy’s cumulative biological effects constitute a critical foundation for its enhanced therapeutic efficacy.
4. Safety and Scalability
Adverse reactions were mainly abdominal distension, abdominal pain, chest pain, and vomiting, all within tolerable limits; no brain injury events occurred under head ice‑pillow protection, and liver and kidney functions remained normal, thereby confirming the safety of local hyperthermic chemotherapy. At the treatment‑concept level, the observation group used a large volume of warm saline for intracavitary fluid replacement and irrigation, effectively cleansing the body cavity and fundamentally reducing the likelihood of complications such as intestinal adhesions caused by protein and fibrin coagulation and subsequent adhesion within the effusion. On the procedural level, the observation group employed the TRL2000 device—the first‑generation intracavitary hyperthermic perfusion chemotherapy system developed by Xi’an Good Doctor Medical Science and Technology Co., Ltd.—which requires no operating‑room conditions and can be performed directly in the oncology ward, thus lowering the equipment’s barrier to entry. The study was independently conducted by the Oncology Department of the People’s Hospital of Xingan County, Jiangxi Province, which to some extent also validates its feasibility in primary‑care settings.
Key words:
Related News